Financial insights of SER

MyFinsight

For the quarter ending 2025-09-30, SER made $6,097,000 in revenue. -$4,585,000 in net income. Net profit margin of -75.20%.

Unit: Dollar

Income Statement	2025-09-30	2025-06-30	2025-03-31	2024-12-31
Total revenues-Grant Revenues	0	-	-	-
Total revenues	0	130,000	-	-4,500
Research and development	3,651,000	3,152,000	2,951,000	1,735,500
General and administrative	2,741,000	2,543,000	2,907,000	2,195,000
Total operating expenses	6,392,000	5,695,000	5,858,000	3,930,500
Loss from operations	-6,392,000	-5,565,000	-5,858,000	-3,935,000
Other income, net	-	-	47,000	57,000
Interest expense	6,000	9,000	-	134,000
Change in fair value of convertible promissory notes	0	0	-	-
Change in fair value of warrants	-1,044,000	956,000	-989,000	1,403,500
Gain on warrants expiration	724,000	-	-	-
Change in fair value of convertible promissory notes	-	-	-	40,500
Other income, net	35,000	68,000	-	-
Total other income, net	1,797,000	-897,000	1,036,000	-4,948,500
Net (loss) income	-4,595,000	-6,462,000	-4,822,000	-8,883,500
Net loss attributable to noncontrolling interest	-10,000	-14,000	-9,000	-6,000
Net (loss) income attributable to serina therapeutics, inc	-4,585,000	-6,448,000	-4,813,000	-8,877,500

Basic (in shares)	10,339,000	10,004,000	9,756,000	-750,257
Basic (in usd per share)	-0.45	-0.66	-0.49	-1.14
Diluted ( in shares)	10,339,000	10,004,000	9,756,000	-1,701,078.5
Diluted (in usd per share)	-0.45	-0.66	-0.49	-1.075